{"id":"NCT00362336","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV","officialTitle":"Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB® Concomitantly Administered With Engerix B® Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-05","completion":"2009-08","firstPosted":"2006-08-10","resultsPosted":"2014-05-02","lastUpdate":"2014-05-02"},"enrollment":622,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B","Polio","Diphtheria","Pertussis","Haemophilus Influenzae Type b"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-PRP~T","otherNames":[]},{"type":"BIOLOGICAL","name":"CombAct-HIB®","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix B® Pediatric","otherNames":[]}],"arms":[{"label":"Group 1: DTaP-IPV-Hep B-PRP-T","type":"EXPERIMENTAL"},{"label":"Group 2: CombAct-HIB™ + OPV","type":"EXPERIMENTAL"},{"label":"Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule\n\nThe primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP\\~T combined vaccine does not induce lower immune responses than CombAct-HIB® with Engerix B® Paediatric and OPV in terms of seroprotection rates to Diphtheria (D), Tetanus (T), polio, Hepatitis B (HB), and Polyribosyl ribitol phosphate (PRP), one month after a 3-dose primary series (6, 10, and 14 weeks) with no HB vaccination at birth.\n\nThe secondary Objectives are:\n\nTo describe the safety in terms of any adverse events in the first 28 days after each injection and any serious adverse events during the entire trial.\n\nTo describe Immunogenicity after the primary series and prior to and after a booster vaccination.","primaryOutcome":{"measure":"Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV)","timeFrame":"1 month post-Dose 3","effectByArm":[{"arm":"DTaP-IPV-Hep B-PRP~T Group","deltaMin":176,"sd":null},{"arm":"CombAct-Hib™ + Engerix B™ + OPV Group","deltaMin":185,"sd":null},{"arm":"DTaP-IPV-Hep B-PRP~T (Engerix B™ at Birth) Group","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":2,"countries":["South Africa"]},"refs":{"pmids":["21289531"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":243},"commonTop":["Injection Site Pain","Crying","Injection Site Erythema","Irritability","Somnolence"]}}